title: A specific radioimmunoassay for the measurement of gadoteridol, a contrast agent for magnetic resonance imaging in biological fluids.
abstract: Gadoteridol, a nonionic gadolinium chelate, is currently being evaluated for contrast-enhanced magnetic resonance imaging. A radioimmunoassay (RIA) has been developed for the measurement of gadoteridol in biological fluids. The RIA has a range of 0 to 25 micrograms/mL and has the sensitivity to detect 0.05 microgram/mL of gadoteridol. Satisfactory zero binding and sensitivity were obtained after an overnight incubation at 4 degrees C. Separation of the antibody-bound and free radiolabel was achieved with 12.5% polyethylene glycol. A quantitative recovery of the exogenous analyte was obtained at all concentrations of gadoteridol tested. Linearity in both serum and urine was satisfactory. Intraassay coefficients of variation were 6.4 and 2.8% for the low and medium controls, respectively. Interassay coefficients of variation were 5.4, 3.8, and 12.2% for the low, medium, and high controls, respectively. Cross reactivities of the ligand 5 and the calcium salt 6 were 37 and 29%, respectively. Clinical samples from the ascending dosage studies were analyzed by the gadoteridol RIA. The results obtained from the serum specimens demonstrated an excellent linear proportionality between drug concentration in blood and administered dosage of gadoteridol. Cumulative urinary excretion data showed that 94% of the drug was excreted in the urine within 24 h.
authors.affiliation: Radioimmunology Department, Bristol-Myers Squibb Pharmaceutical Research Institute, New Brunswick, NJ 08903-0191.
authors.forename: M D
authors.initials: MD
authors.lastname: Ogan
authors.forename: A C
authors.initials: AC
authors.lastname: Reiss
authors.forename: E M
authors.initials: EM
authors.lastname: Croze
authors.forename: E M
authors.initials: EM
authors.lastname: Jagoda
authors.forename: B C
authors.initials: BC
authors.lastname: Stouffer
authors.forename: S
authors.initials: S
authors.lastname: Mantha
authors.forename: H M
authors.initials: HM
authors.lastname: Tsay
authors.forename: F J
authors.initials: FJ
authors.lastname: Yost
authors.forename: J I
authors.initials: JI
authors.lastname: Tu
mesh_terms: D000818:Animals; D000918:Antibody Specificity; D001682:Biological Availability; D003287:Contrast Media / Q000032:analysis* / Q000493:pharmacokinetics; D005682:Gadolinium; D006571:Heterocyclic Compounds / Q000032:analysis* / Q000276:immunology / Q000493:pharmacokinetics; D006801:Humans; D007202:Indicators and Reagents; D008279:Magnetic Resonance Imaging; D009942:Organometallic Compounds / Q000032:analysis* / Q000276:immunology / Q000493:pharmacokinetics; D011817:Rabbits / Q000276:immunology; D011863:Radioimmunoassay; D012044:Regression Analysis
chemical_list: D003287:Contrast Media; D006571:Heterocyclic Compounds; D007202:Indicators and Reagents; D009942:Organometallic Compounds; C062402:gadoteridol; D005682:Gadolinium